Photodynamic theranostics in surgical treatment of patients with peritoneal carcinomatosis

封面


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The role and possibilities of photodynamic theranostics, including fluorescence diagnostics and photodynamic therapy, in complex cytoreductive surgical treatment of peritoneal carcinomatosis, evaluation of the effectiveness of its use, and analysis of the impact of this approach on the results of surgical intervention were investigated. Available modern domestic and foreign scientific literature were analyzed using PubMed, eLibrary.ru, and Google Scholar. Peritoneal carcinomatosis is characterized by the spread of tumor cells in the peritoneum and can be either a primary form of a tumor, such as pseudomyxoma and mesothelioma, or metastatic spread of cancer, most often of the gastrointestinal tract or gynecological organs. Surgical treatment of peritoneal carcinomatosis is crucial in the complex treatment of this category of patients, which determines the importance of further improvement of cytoreductive technologies. The extent of peritoneal dissemination during surgery may be underestimated, since intraoperative diagnosis is based solely on visual inspection and palpation. Thus, the use of phototheranostics — fluorescence diagnostics and photodynamic therapy — is a promising direction that has an antitumor effect and visualizes the peritoneum involved in the oncological process, which is beneficial for determining the required volume of peritonectomy. Currently, they are promising methods in the treatment of tumors of various locations. Both techniques are linked by the principle of theranostics (including diagnosis of the disease and personalized treatment of the patient) and imply the use of specific dyes (photosensitizers) and their ability to be excited under the influence of light of a certain wavelength. The therapeutic and diagnostic potential of phototheranostics in the complex surgical treatment of peritoneal carcinomatosis is emphasized; the main problems are described and prospects for the development of this technology are presented based on retrospective and prospective studies and systematic reviews.

全文:

受限制的访问

作者简介

Dmitry Rudakov

Kirov Military Medical Academy

编辑信件的主要联系方式.
Email: rudakov.d-a@yandex.ru
ORCID iD: 0009-0004-0414-4471
SPIN 代码: 7395-3860

adjunct

俄罗斯联邦, Saint Petersburg

Grigory Tochilnikov

Petrov National Medical Research Center of Oncology

Email: gr75@mail.ru
ORCID iD: 0000-0003-4232-8170
SPIN 代码: 4366-6930

MD, Cand. Sci. (Med.)

俄罗斯联邦, Saint Petersburg

Ivan Soloviev

Mariinskaya Hospital

Email: ivsolov@yandex.ru
ORCID iD: 0000-0001-9646-9775
SPIN 代码: 6703-4852

MD, Dr. Sci. (Med.), professor

俄罗斯联邦, Saint Petersburg

Dmitry Surov

Kirov Military Medical Academy

Email: rudakov.d-a@yandex.ru
ORCID iD: 0000-0002-4519-0018
SPIN 代码: 5346-1613

MD, Dr. Sci. (Med.), associate professor

俄罗斯联邦, Saint Petersburg

Denis Dymnikov

Kirov Military Medical Academy

Email: rudakov.d-a@yandex.ru
ORCID iD: 0000-0003-1644-1014
SPIN 代码: 6945-7148

MD, Cand. Sci. (Med.)

俄罗斯联邦, Saint Petersburg

参考

  1. Xu S, Bulin AL, Hurbin A, et al. Photodynamic diagnosis and therapy for peritoneal carcinomatosis: Emerging perspectives. Cancers. 2020;12(9):24–91. doi: 10.3390/cancers12092491
  2. Flanagan M, Solon J, Chang KH, et al. Peritoneal metastases from extra-abdominal cancer — A population-based study. Eur J Surg Oncol. 2018;44(11):1811–1817. doi: 10.1016/j.ejso.2018.07.049
  3. Kaprin AD, Starinsky VV, Shakhzadova AO, editors. The state of oncological care to the population of Russia in 2021. Moscow: P.A. Herzen Moscow State Medical Research Institute − branch of the Federal State Budgetary Institution “NMIC of Radiology”; 2022. 239 р. (In Russ.)
  4. Vassos N, Piso P. Metastatic colorectal cancer to the peritoneum: current treatment options. Curr Treat Options Oncol. 2018;19(10):49. doi: 10.1007/s11864-018-0563-8
  5. Breuer E, Hebeisen M, Schneider MA, et al. Site of recurrence and survival after surgery for colorectal peritoneal metastasis. J Natl Cancer Inst. 2021;113(8):1027–1035. doi: 10.1093/jnci/djab001
  6. Solodkiy VA, Fomin DK, Goncharov SV, Kukushkina SA. Modern approaches to the treatment of peritoneal carcinomatosis from gastric cancer (literature review). Siberian Journal of Oncology. 2022;21(1):122–129. EDN: WPIKU doi: 10.21294/1814-4861-2022-21-1-122-129
  7. Coccolini F, Gheza F, Lotti M, et al. Peritoneal carcinomatosis. World J Gastroenterol. 2013;19(41):6979–6994. doi: 10.3748/wjg.v19.i41.6979
  8. Kitai T. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis: a systematic review including evidence from Japan. Surg Today. 2021;51(7):1085–1098. doi: 10.1007/s00595-020-02180-7
  9. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010;177(3):1053–1064. doi: 10.2353/ajpath.2010.100105
  10. Azaïs H, Estevez JP, Foucher P, et al. Dealing with microscopic peritoneal metastases of epithelial ovarian cancer. A surgical challenge. Surg Oncology. 2017;26(1):46–52. doi: 10.1016/j.suronc.2017.01.001
  11. Nguyen VT, Prosvetov VA, Bromberg BB, et al. The possibility of using of cytoreductive technologies in the surgical treatment of patients with complicated disseminated tumors of the abdominal cavity and pelvic cavity. Bulletin of Pirogov National Medical and Surgical Center. 2023;18(1):74–80. EDN: UTPVTV doi: 10.25881/20728255_2023_18_1_74
  12. Spiliotis J, Kopanakis N, Prodromidou A, et al. Peritoneal sarcomatosis: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Surg Innov. 2021;28(3):394–395. doi: 10.1177/1553350620958259
  13. Sugarbaker PH. Prevention and treatment of peritoneal metastases: a comprehensive review. Indian J Surg Oncol. 2019;10(1):3–23. doi: 10.1007/s13193-018-0856-1
  14. Yonemura Y, Endou Y, Sasaki T, et al. Surgical treatment for peritoneal carcinomatosis from gastric cancer. Eur J Surg Oncol. 2010;36(12):1131–1138. doi: 10.1016/j.ejso.2010.09.006
  15. Glockzin G, Zeman F, Croner RS, et al. Perioperative systemic chemotherapy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy in patients with colorectal peritoneal metastasis: results of the prospective multicenter phase 2 combatac trial. Clin Colorectal Cancer. 2018;17(4):285–296. doi: 10.1016/j.clcc.2018.07.011
  16. Narasimhan V, Britto M, Pham T, et al. Evolution of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: 8-year single-institutional experience. Dis Colon Rectum. 2019;62(10):1195–1203. doi: 10.1097/dcr.0000000000001456
  17. Quénet F, Elias D., Roca L., et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256–266. doi: 10.1016/s1470-2045(20)30599-4
  18. Abboud K, André T, Brunel M, et al. Management of colorectal peritoneal metastases: Expert opinion. J Visc Surg. 2019;156(5): 377–379. doi: 10.1016/j.jviscsurg.2019.08.002
  19. Prosvetov VA, Surov DA, Gaivoronsky IV, Nguyen VT. Innovative technology of total parietal peritonectomy for peritoneal carcinomatosis. Russian Military Medical Academy Reports. 2022;41(2):143–149. EDN: WWHFDH doi: 10.17816/rmmar104695
  20. Kyang LS, Dewhurst SL, See VA, Alzahrani NA, Morris DL. Outcomes and prognostic factors of cytoreductive surgery and perioperative intraperitoneal chemotherapy in high-volume peritoneal carcinomatosis. Int J Hyperthermia. 2022;39(1): 1106–1114. doi: 10.1080/02656736.2022.2112625
  21. Somashekhar SP, Ashwin KR, Yethadka R, et al. Impact of extent of parietal peritonectomy on oncological outcome after cytoreductive surgery and HIPEC. Pleura and Peritoneum. 2019;4(4):20190015. doi: 10.1515/pp-2019-0015
  22. Mercier F, Mohamed F, Cazauran JB, et al. An update of peritonectomy procedures used in cytoreductive surgery for peritoneal malignancy. Int J Hyperthermia. 2019;36(1):744–752. doi: 10.1080/02656736.2019.1635717
  23. Karadayi K, Bostanci ME, Mollaoglu MC, Karabacak U. Cytoreductive surgery and perioperative intraperitoneal chemotherapy experience in peritoneal carcinomatosis: single-center analysis of 180 cases. Int J Surg Oncol. 2021;2021:8851751. doi: 10.1155/2021/8851751
  24. Nguyen VT, Prosvetov SA, Bromberg BB, et al. Historical, pathogenetic and clinical aspects of peritonectomy in patients with peritoneal canceromatosis. Medline.ru. 2022;23(2):705–721. EDN: MKHCUY
  25. Liberale G, Vankerckhove S, Caldon MG, et al. Fluorescence imaging after indocyanine green injection for detection of peritoneal metastases in patients undergoing cytoreductive surgery for peritoneal carcinomatosis from colorectal cancer: A pilot study. Ann Surg. 2016;264(6):1110–1115. doi: 10.1097/sla.0000000000001618
  26. Boogerd LSF, Hoogstins CES, Schaap DP, et al. Safety and effectiveness of SGM-101, a fluorescent antibody targeting carcinoembryonic antigen, for intraoperative detection of colorectal cancer: a dose-escalation pilot study. Lancet Gastroenterol Hepatol. 2018;3(3):181–191. doi: 10.1016/s2468-1253(17)30395-3
  27. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–374. doi: 10.1007/978-1-4613-1247-5_23
  28. Nguyen VT, Prosvetov VA, Bromberg BB, et al. Methods to increase the effectiveness of cytoreductive surgical interventions in patients with complicated disseminated tumors of the abdominal cavity and pelvis. Bulletin of the Russian Military Medical Academy. 2023;25(1):23–32. EDN: DDRMCJ doi: 10.17816/brmma120006
  29. Nguyen VT, Bromberg BB, Novikova MV, et al. Using two-stage cytoreductive surgery in a patient with complicated progressive small intestinal cancer. Bulletin of Pirogov National Medical and Surgical Center. 2022;17(3):142–147. EDN: SLNKVX doi: 10.25881/20728255_2022_17_3_142
  30. Markovich VA, Tuzikov SA, Rodionov EO, et al. Gastric cancer: modern approaches and prospects of treatment for peritoneal carcinomatosis (literature review). Siberian Journal of Oncology. 2021;20(6):104–113. EDN: OPHHFD doi: 10.21294/1814-4861-2021-20-6-104-113
  31. Sugarbaker PH. Peritonectomy procedures. Ann surg. 1995;221(1):29–42. doi: 10.1097/00000658-199501000-00004
  32. Baratti D, Kusamura S, Cabras AD, Deraco M. Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: A controlled study. Ann Surg Oncol. 2012;19(5):1416–1424. doi: 10.1245/s10434-012-2237-2
  33. Somashekhar SP, Ashwin KR, Kumar R, et al. Comparison of outcomes following complete and selective parietal peritonectomy during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer: a study by indian society of peritoneal surface malignancies (ISPSM). Indian J Gynecol Oncol. 2018;16(4). doi: 10.1007/s40944-018-0241-6
  34. Sugarbaker PH. Peritoneum as the first-line of defense in carcinomatosis. J Surg Oncol. 2007;95(2):93–96. doi: 10.1002/jso.20676
  35. Abramovich SG. Phototherapy. Irkutsk: SC RRS SB RAMS; 2014. 200 р. (In Russ.)
  36. Sanarova EV, Lantsova AV, Dmitrieva MV, et al. Photodynamic therapy is a way to improve the selectivity and efficiency of the tumor treatment. Russian Journal of Biotherapy. 2014;13(3):109–118. (In Russ.) EDN: SZVDPR
  37. Papayan GV, Akopov AL. Fluorescence diagnostics in the near infrared range: equipment, application. Journal of Optical Technology. 2016;83(9):33–42. EDN: WRLEEV
  38. Donohoe C, Senge MO, Arnaut LG, Gomes-da-Silva LC. Cell death in photodynamic therapy: From oxidative stress to anti-tumor immunity. Biochim Biophys Acta Rev Cancer. 2019;1872(2):188308. doi: 10.1016/j.bbcan.2019.07.003
  39. Kwiatkowski S, Knap B, Przystupski D, et al. Photodynamic therapy — mechanisms, photosensitizers and combinations. Biomed Pharmacother. 2018;106:1098–1107. doi: 10.1016/j.biopha.2018.07.049
  40. Allison RR. Photodynamic therapy: Oncologic horizons. Future Oncol. 2014;10(1):123–142. doi: 10.2217/fon.13.176
  41. Akopov AL, Kazakov NV, Rusanov AA, Karlson A. The mechanisms of photodynamic action for treating of cancer patients. Biomedical Photonics. 2015;4(2):9–16. EDN: UKTTID doi: 10.24931/2413-9432-2015-4-2-9-16
  42. Suleimanov EA, Khomyakov VM, Serova LG, et al. Intraoperative photodynamic therapy for metastatic peritoneal tumors. Research’n Practical Medicine Journal. 2016;3(3):59–67. EDN: WKUVGF doi: 10.17709/2409-2231-2016-3-3-6
  43. Hahn SM, Fraker DL, Mick R, et al. A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis. Clin Cancer Res. 2006;12(8):2517–2525. doi: 10.1158/1078-0432.ccr-05-1625
  44. Petrovskaya NA, Vozmitel MA, Kharuzhyk SA, Istomin YuP. Multimodal treatment of peritoneal carcinomatosis in experiment. Oncological Journal. 2011;5(4):60–68. (In Russ.) EDN: RUPKWP
  45. Suleimanov EA. Intraoperatsionnaya fluorestsentnaya diagnostika i fotodinamicheskaya terapiya bol’nykh s pervichnymi i metastaticheskimi opukholyami bryushiny [dissertation]. Moscow; 2018. 48 р. (In Russ.)
  46. Krochek IV, Sergiyko SV, Ibatullin RD, Anchugova AE, Grekova NM. Combined treatment of local-regional cancer with replacement of intraoperative photodynamic therapies, first results. In: Topical issues of surgery: Collection of scientific and practical works. 2020;13:167–173. (In Russ.)
  47. Popovkina OE, Kapinus VN, Yaroslavtseva-Isayeva EV, et al. Development of fluorescence diagnosis and photodynamic therapy in A. Tsyb Medical Radiological Research Centre. Radiation and risk. 2022;31(2):139–150. EDN: HWIMME doi: 10.21870/0131-3878-2022-31-2-139-150
  48. Rizvi I, Celli JP, Evans CL, et al. Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer. Cancer Res. 2010;70(22):9319–9328. doi: 10.1158/0008-5472.can-10-1783
  49. Spring BQ, Abu-Yousif AO, Palanisami A, et al. Selective treatment and monitoring of disseminated cancer micrometastases in vivo using dual-function, activatable immunoconjugates. Proc Natl Acad Sci USA. 2014;111(10):E933–E942. doi: 10.1073/pnas.1319493111
  50. Xin J, Wang S, Zhang L, et al. Comparison of the synergistic anticancer activity of AlPcS4 photodynamic therapy in combination with different low-dose chemotherapeutic agents on gastric cancer cells. Oncol Rep. 2018;40(1):165–178. doi: 10.3892/or.2018.6438
  51. Korshunova OV, Plekhova NG. Photodynamic therapy in oncology: present and future. Pacific Medical Journal. 2020;4(82):15–19. EDN: ALTTRK doi: 10.34215/1609-1175-2020-4-15-19
  52. Zakharenko AA, Natkha AS, Trushin AA, et al. Pressured itraperitoneal aerosol chemotherapy — a new effective way of treatment of implantation metastasises (Review). Medline.ru. 2015;16:834–849. EDN: ZEQGHV
  53. Almyashev AZ. Modern laser information technologies in clinical oncology. Medicus. 2021;6(42):30–49. EDN: OCDXVX
  54. Riabov MV. Photodynamic therapy. Current state and prospects of development. In: Lasers in science, technology, medicine: Collection of scientific papers of the XXXI international conference. Moscow; 2020. Р. 178–182.

补充文件

附件文件
动作
1. JATS XML

版权所有 © Eco-Vector, 2024



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 77762 от 10.02.2020.


##common.cookie##